Original Contributions |
From the Department of Pathology, University of Chicago, Chicago, Ill.
Correspondence to Alex Morla, PhD, Department of Pathology, MC 6079, Committee on Cancer Biology, University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637. E-mail amorla{at}midway.uchicago.edu
| Abstract |
|---|
|
|
|---|
5ß1) distribution revealed that
III1-C did not inhibit
5ß1 localization to focal
contacts. Moreover, III1-C had no effect on the relative
expression levels of seven different integrin subunits on HUASMCs.
However, III1-C did inhibit fibronectin matrix assembly by
rat aortic smooth muscle cells, HUASMCs, A7r5 cells, IMR-90 cells, and
endothelial cells. An analysis of fibronectin
synthesis indicated that the inhibition of fibronectin matrix assembly
by III1-C was not due solely to a decrease in fibronectin
synthesis. Finally, treatment of HUASMCs with anti-fibronectin
monoclonal antibody L8 (which is known to inhibit fibronectin matrix
assembly) also decreased the rate of HUASMC DNA synthesis. These
results demonstrate that III1-C inhibits VSMC proliferation
and suggest that this effect may be mediated by the inhibition of
fibronectin matrix assembly.
Key Words: extracellular matrix integrin laminin Matrigel
| Introduction |
|---|
|
|
|---|
The ECM has also been found to regulate VSMC phenotype. VSMCs that are removed from their tissue of origin and placed in cell culture gradually modulate from a contractile to a synthetic phenotype in a manner that is thought to recapitulate the modulation seen in disease states in vivo.5 6 7 8 ECM molecules such as collagen, FN, and laminin can influence the phenotypic modulation of VSMCs in culture.9 For example, VSMCs grown on fibrillar collagen matrices do not proliferate, whereas those grown on monomeric collagen coated onto a dish do proliferate.10 11 This inhibition of VSMC proliferation by fibrillar collagen has been found to be due to upregulation of cdk2 inhibitors.12
Another example of the regulation of VSMC modulation by ECM molecules can be seen with laminin and FN. VSMCs that are cultured on laminin retain a contractile phenotype longer than do cells cultured on FN.13 14 15 Moreover, cells cultured on laminin plus synthetic peptides containing the RGD integrinbinding motif found in FN retain a contractile phenotype longer than do cells cultured on laminin alone.13 15 The experiments described above do not distinguish whether the maintenance of a contractile phenotype was due to the inhibition of integrins binding to FN or to the inhibition of FN matrix assembly.
FN matrix assembly is a cell-mediated process that involves the binding
of FN to cell surface receptors (integrins) and to cell-associated FN
molecules.16 17 The interaction between the FN
receptor integrin
5ß118 and the RGD site of
FN19 is required for matrix assembly in most
cellular systems.20 21 22 23 24 25 However, other
RGD-binding integrins (eg,
IIbß3 and
vß3) can support FN
matrix assembly.26 27
FN matrix assembly also requires specific FN-FN binding interactions at the cell surface. The regions in FN that have been shown to be involved in FN-FN binding and are required for proper matrix assembly of the molecule include the N-terminal 70-kD region, the first type III repeat, and the 10th type III repeat.16 17 28 29 30 31 32 33 34 35 36 We have previously identified a recombinant protein representing a C-terminal portion of the first type III repeat in FN (protein III1-C) that is able to induce spontaneous in vitro disulfide cross-linking of FN.37 The III1-C protein also enhances FN matrix assembly on CHO cells and enhances the binding of cells to FN.
As described above, RGD peptides enhance the maintenance of the contractile phenotype in VSMCs cultured on laminin; however, it is not known whether this is due to the inhibition of integrins binding to FN or to the inhibition of FN matrix assembly. Moreover, although culturing cells on dimeric FN is known to accelerate VSMC phenotypic modulation, the influence of VSMC FN matrix assembly on growth and modulation is not known. In the present study, we have used the III1-C protein to alter the FN matrix assembly of VSMCs to test the role of FN matrix assembly on VSMC growth. The results indicate that III1-C inhibits VSMC FN matrix assembly and that this leads to an inhibition of cell proliferation.
| Materials and Methods |
|---|
|
|
|---|
5 mAb was from PharMingen, and anti-phosphotyrosine
rabbit serum was a kind gift of Dr Wei Li (University of Chicago, Ill).
Antibodies used for FACS analysis were as follows: anti-
1,
TS2/7 (ATCC); anti-
2, AK-7 (PharMingen); anti-
3, A3-X8 (gift of
Drs R. Pasqualini and E. Ruoslahti, Burnham Institute, La Jolla,
Calif); anti-
v (Chemicon); anti-ß1, TS2/16 (ATCC); anti-ß3,
CD-61 (Becton Dickinson); and anti-ß5, IA9 (gift of Drs R. Pasqualini
and E. Ruoslahti). Growth factorreduced Matrigel was obtained from
Becton Dickinson. mAb L8 was a kind gift of Dr Victor Koteliansky
(Institute of Cardiology, Moscow, Russia).
[3H]Thymidine (50 Ci/mmol) was obtained from
Amersham. 35S-Translabel was from ICN. SDS-PAGE
gels (4% to 20% polyacrylamide gradient) were from Novex.
Protease inhibitor cocktail used in immunoprecipitation was
the Complete protease inhibitor cocktail from
Boehringer-Mannheim. Protein A Sepharose was from Pharmacia
LKB. All other reagents were purchased from Sigma.
Cell Culture
HUASMCs were cultured in Sm-GM2 medium, which contains 5% FCS,
10 ng/mL human epidermal growth factor, 2 ng/mL human fibroblast growth
factor, 5 µg/mL insulin, 50 µg/mL gentamicin, and 50 ng/mL
amphotericin. HUASMCs were typically between passages 5 and 9 for
experiments. Primary rat aortic SMCs were a kind gift of Dr Michael
Parmacek (University of Chicago, Ill) and were grown in either Sm-GM2
or 50% DMEM, 50% Ham's F-12 plus 10% FBS, and glutamine Pen-Strep.
HUVECs were isolated from umbilical veins as described
previously.38 HUVECs were cultured in Dulbecco's
medium 199 supplemented with 20% FBS, 50 µg/mL heparin, 30 µg/mL
endothelial cell growth supplement, and glutamine
Pen-Strep and were in passage 1 for the present study. IMR-90
cells, NIH 3T3 cells, and A7r5 cells were cultured in DMEM supplemented
with 10% FBS and glutamine Pen-Strep. IMR-90 cells were in passage 12
for the present study.
Recombinant Protein Production
Proteins III1-C and
III11-C (previously called III11, Ref
37) were produced in bacteria and purified as described
previously.37 Stock protein solutions were
typically 800 µmol/L for III1-C and
260 µmol/L for III11-C in PBS.
Cell Growth Analyses
For DNA synthesis analysis, wells of 24-well cluster
dishes (Fisher) either were left uncoated or were coated with 20
µg/mL FN, 20 µg/mL laminin, or 100 µg/mL growth factorreduced
Matrigel. All protein solutions were in PBS. After coating at RT for 1
hour, wells were washed extensively with PBS, and then cells were
added. Cells were plated at a density of 1.5 to
3x103 per well and then allowed to attach and
spread for 30 minutes at 37°C. III1-C,
III11-C, or mAb L8 was then added to the
appropriate wells, and the cells were cultured in the presence of these
treatments for the duration of the experiment. At the appropriate time,
the rate of DNA synthesis was measured by 1- or 2-hour pulse labelings
with 10 µCi/mL [3H]thymidine as previously
described.39 Student's t test was
performed to determine the statistical significance of the differences
seen between III1-Ctreated cultures and
control-treated cultures.
The effect of III1-C on cell growth was also measured by determining the increase in cell number of the cultures. Wells of six-well cluster dishes either were left uncoated or were coated with 20 µg/mL FN as described above. HUASMCs were plated at a density of 10 000 cells per well and then allowed to attach and spread for 30 minutes at 37°C. III1-C or III11-C was then added to the appropriate wells, and the cells were cultured in the presence or absence of these recombinant proteins for the duration of the experiment. After 1, 3, and 7 days of culturing, cells were harvested by trypsinization, and the number of cells in each population was measured with a hemocytometer.
Immunofluorescence Assays and Quantification of
FN Matrix Assembly
Cells were cultured as described for DNA synthesis
analysis above, except that glass coverslips were placed in the
wells of the 24-well dishes before coating with ECM proteins. After 2
to 4 days in culture, cells were fixed for 30 minutes at RT with 3.7%
paraformaldehyde and 60 mmol/L sucrose in TBS.
Cells were then washed with 0.5% goat serum/TBS,
permeabilized with 1% Triton X-100 in TBS, washed
again, and then incubated for 2 hours at RT with either 10 µg/mL of
rabbit polyclonal anti-human FN IgG in 5% goat serum/TBS (for Figs 6
and 7
) or 1:1000 dilution of anti-phosphotyrosine rabbit serum plus 20
µg/mL anti-
5 mAb in 5% goat serum/TBS (for Fig 4
). The cells were
then washed and incubated for 1 hour at RT with either FITC goat
anti-rabbit antibodies or FITC goat anti-rabbit antibodies plus Texas
red goat anti-mouse antibodies. The coverslips were mounted and
visualized with a x40 oil-immersion objective on a Zeiss Axioskop
fluorescence microscope, and images were captured by using a
Photometrics PXL CCD camera connected to a Silicon Graphics workstation
(Fig 4
) or connected to an Apple Macintosh using the OpenLab software
suite (Figs 6
and 7
). For Figs 4
and 6
, the images were composited and
labeled in Adobe Photoshop and output to a Kodak dye-sublimation
printer. The images were not altered in any way on the computers.
|
|
|
The amount of FN matrix assembly was quantified as follows: In this
immunofluorescence assay, FN fibrils were brighter
than the surrounding fibril-free areas and brighter than the background
fluorescence emitted by cell bodies (see Fig 6
for examples).
Therefore, the amount of area occupied by FN fibrils in each image was
determined by using the NIH Image v1.6.1 program to measure the amount
of area occupied by pixels that were brighter than the background
fluorescence emitted from cell bodies. More than 20 images from
each condition (III1-C and
III11-C) were analyzed, and then the
averages and standard deviations were calculated. The data were also
analyzed by Student's t test.
Apoptosis Assays
Cells were cultured on coverslips as described for
immunofluorescence analysis above. At the
appropriate times, cells were fixed for 30 minutes at RT with 3.7%
paraformaldehyde and 60 mmol/L sucrose in TBS.
Cells were washed three times with PBS, permeabilized
with 0.5% Triton X-100 and 0.1% sodium citrate in PBS, washed again,
and then incubated for 1 hour at 37°C with the TUNEL assay solution
(from the In Situ Cell Death Detection Kit, Fluorescein,
Boehringer-Mannheim). Cells were then washed two times with PBS and
incubated for 20 seconds with 1 mmol/L DAPI in PBS. Cells were
washed two times with PBS, and the coverslips were mounted and
analyzed with a x20 oil-immersion objective on a Zeiss
Axioskop fluorescence microscope.
FN Synthesis Assay
HUASMCs were cultured as described above for DNA synthesis
assays, except that 10-cm-diameter dishes were used instead of 24-well
plates. After 24 hours of culturing in the presence or absence of
either III1-C or III11-C,
cells were washed two times, 5 minutes per wash, with Met/Cys-free
DMEM+10% FBS+glutamine Pen-Strep. Cells were then cultured in 3 mL of
fresh Met/Cys-free medium±III1-C or
III11-C (where appropriate) plus 200 µCi
35S-translabel for 30 minutes at 37°C. Plates
were washed with ice-cold PBS and then lysed in RIPA buffer plus
protease inhibitor cocktail. Lysates were precleared by
centrifugation at 12 000g for 15 minutes at
4°C, and then the amount of 35S incorporated
into TCA-precipitable counts was measured. Lysates were brought to
equal TCA-precipitable counts per milliliter, and then FN was
immunoprecipitated with polyclonal anti-FN IgG. The antibodies were
collected onto protein A Sepharose beads, washed four times with RIPA,
and then boiled in SDS-PAGE sample buffer containing 2-mercaptoethanol.
Samples were electrophoresed on a 4% to 20% polyacrylamide
gradient gel, the gel was dried, and the radioactive proteins were
detected by an 18-hour exposure with a Molecular Dynamics
PhosphorImager.
Integrin Expression Analysis
HUASMCs were cultured as described above for DNA synthesis
assays, except that cells were cultured on 10-cm-diameter dishes
instead of 24-well dishes (cells were seeded at
3x105 cells per 10-cm dish). After 24 hours of
culturing in the presence or absence of either
III1-C or III11-C, cells
were harvested by trypsinization and then washed with ice-cold FACS
wash solution (0.5% goat serum and 30 mmol/L
NaN3, in PBS). Cells (30 000 cells per sample)
in suspension were incubated individually with anti-integrin mAbs
(1:500 dilution of ascites in FACS wash solution) for 30 minutes at
4°C. Cells were then washed three times with FACS wash solution, and
then the cells were incubated with FITC goat anti-mouse IgG diluted in
FACS wash solution. After 30 minutes with the secondary antibody, cells
were washed three times, and then they were resuspended in PBS plus
0.2% paraformaldehyde. The samples were then
analyzed on a FACScan flow cytometer (Becton Dickinson). The
data were graphed, and the mean fluorescence intensities were
calculated by using the WinMDI 2.5 program by Joe Trotter of the
Scripps Research Institute (La Jolla, Calif).
| Results |
|---|
|
|
|---|
|
The effect of III1-C on total cell number was
consistent with the effect of the peptide on DNA synthesis
shown above. Over the span of 7 days, HUASMCs cultured on uncoated
dishes increased in cell number by 460% (Fig 1B
, control). At the same
time, cells cultured on FN or on FN plus the control protein
III11-C in the medium increased by 660% and
650%, respectively (Fig 1B
, FN and FN+11C). In contrast, cells
cultured on FN-coated dishes plus III1-C in the
medium increased in cell number by only 75% (Fig 1B
, FN+C). Thus, both
proliferation assays ([3H]thymidine
incorporation and cell counting) indicated that
III1-C inhibits HUASMC growth.
The time course of the effect of III1-C on HUASMC
DNA synthesis was determined by measuring the rate of DNA synthesis
either 3, 5, 24, or 48 hours after the addition of
III1-C. III1-C had no
effect on VSMC DNA synthesis after 3 and 5 hours; however, at 24 and 48
hours, III1-C inhibited DNA synthesis by 75% and
81%, respectively, compared with the untreated cultures (Fig 2
). As described in "Discussion,"
this lag in inhibition of DNA synthesis by III1-C
may indicate that III1-C inhibits HUASMC growth
at a specific stage in the cell cycle (eg, at the
G1- to S-phase transition).
|
One possible explanation for the inhibition of cell growth by III1-C is that III1-C may be inducing HUASMC apoptosis. To test this, HUASMCs were treated with or without III1-C for 1 to 4 days, and at each day the percentage of cells in apoptosis was determined by DAPI staining of DNA and by TUNEL assay. All cultures gave similar results: <1% of the cells were apoptotic in all of the culture conditions (not shown). Thus, III1-C does not induce HUASMC apoptosis, and the inhibition of DNA synthesis must be due to a mechanism other than induction of programmed cell death.
To determine whether III1-C could inhibit the
growth of other cell types, we tested the effect of the peptide on
primary rat aortic SMCs, the A7r5 VSMC line, IMR-90 and NIH 3T3
fibroblasts, and endothelial cells. Treatment of IMR-90
fibroblasts and HUVECs with III1-C resulted in no
change in DNA synthesis compared with untreated or control-treated
cultures (Fig 3
).
III1-C also did not inhibit the growth of NIH 3T3
cells (not shown). In addition, III1-C had no
significant effect on the proliferation of an established rat VSMC
line, A7r5 (Fig 3
). However, III1-C did
significantly inhibit the proliferation of primary rat aortic SMCs (Fig 3
). These results indicate that III1-C does not
inhibit the growth of various cell cultures and cell lines but does
inhibit the growth of normal diploid rat and human VSMCs.
|
The mechanism by which III1-C inhibits VSMC
growth was addressed by analyzing the effect of
III1-C on FN receptors. For nontransformed
fibroblasts it has been shown that cell adhesion to the ECM is
essential for progression through the cell
cycle.40 41 Thus, if III1-C
disrupts the adhesion of VSMCs to the FN-coated on the dish, this could
potentially lead to cell cycle arrest. The main FN receptor on SMCs is
the integrin
5ß1; thus, we analyzed the effect of
III1-C on
5ß1-FN interactions. The only ECM
ligand for
5ß1 is FN, and when
5ß1 is bound to FN, the
integrin becomes concentrated in focal
adhesions.42 43 44 45 Moreover, when
5ß1 is not
bound to FN, it remains diffusely distributed across the cell membrane,
even if the cell contains focal contacts.45 Thus,
the only time
5ß1 is found in focal contacts is when it is bound
to its ligand, FN, in the ECM. Therefore, one measure of
5ß1
binding to FN in cultured cells is to determine the subcellular
distribution of
5ß1; localization of
5ß1 to focal contacts
indicates that this integrin is bound to FN. Anti-phosphotyrosine
antibodies were used to identify the locations of focal contacts, as
has been previously shown.46 47 48 In control cells
seeded onto uncoated plastic,
5ß1 was diffusely distributed, even
though these cells did contain prominent focal contacts (Fig 4
, control panels). A few focal contacts
did contain
5ß1, but most focal contacts in the control cultures
were devoid of
5ß1. This is consistent with the
well-established finding that cells seeded onto uncoated culture dishes
in the presence of serum attach to and spread on
vitronectin from the serum that has adhered to the culture
dish and that the main vitronectin receptors in VSMCs are
v-containing integrins (not
5ß1).
In contrast to the results described above with uncoated wells, most of
the focal adhesions in cells cultured on FN-coated wells contained
5ß1 (Fig 4
, FN, FN+C, and FN+11C panels). Note that in the
cultures treated with III1-C, the
5ß1
staining of the focal contacts was perhaps less intense than in the
cultures treated with the control protein
III11-C. However, most of the focal contacts in
these cells did contain
5ß1. This result indicates that
III1-C does not inhibit the localization of
5ß1 to focal contacts.
The effect of III1-C on overall integrin
expression was also determined. III1-Cand
III11-Ctreated HUASMCs were subjected to FACS
analysis with a battery of anti-integrin antibodies. HUASMCs
were found to express
1ß1,
2ß1,
3ß1,
5ß1, and
vß3, but no
vß5 (Fig 5
shows
results with anti-
2, -
3, -
5, and -ß1) (note that the cells
may also express
vß1, but the available antibodies cannot
specifically distinguish that integrin subunit combination in a FACS
analysis). Treatment of HUASMCs with
III1-C resulted in no significant change in
integrin expression (Fig 5
;
1,
v, and ß3 also did not change
but are not shown). Thus, III1-C did not reduce
relative integrin expression levels on the VSMCs.
|
The mechanism by which III1-C inhibits VSMC
growth was addressed next by analyzing the effect of
III1-C on FN matrix assembly. All of the cell
types tested (HUASMCs, A7r5 cells, IMR-90 cells, and HUVECs) assembled
an FN matrix, although the most extensive fibrils were produced by the
HUASMCs and the IMR-90 fibroblasts (Fig 6
, control panels). Cells grown on FN or
additionally treated with the control protein
III11-C also assembled fibrillar FN matrices (Fig 6
, FN and FN+11C panels). By contrast,
III1-Ctreated cells in each case produced
short, faint, fibril-like stitches that stained with anti-FN antibodies
but had none of the typical prominent FN fibrils seen in the control
cultures (Fig 6
, FN+C panels).
The effect of III1-C on FN matrix assembly was
quantified next. Rat aortic SMCs were grown in the presence of either
III1-C or III11-C for 3
days, and then the cultures were analyzed by
immunofluorescence with anti-FN antibodies as
described above. The amount of area occupied by FN fibrils was
quantified in randomly chosen fields. The data demonstrate that
III1-C inhibited FN matrix assembly by
90%
(Fig 7
). The results shown in Figs 6
and 7
indicate that III1-C significantly inhibited FN
fibril formation in each of the cell types tested.
One way in which III1-C could potentially reduce
FN matrix assembly is by inhibiting FN synthesis. The effect of
III1-C on HUASMC FN synthesis was studied by
labeling proteins with 35S-translabel and then
immunoprecipitating with anti-FN antibodies. The
35S labeling revealed that overall protein
synthesis was 60% to 65% lower (on a per-cell basis) in
III1-Ctreated cells than in control-treated
cells (data not shown). However, III1-C had no
specific effect on FN synthesis. When cell lysates were equalized for
total TCA-precipitable counts, the amount of
35S-labeled FN produced from
III1-Ctreated and
III11-Ctreated cells was equivalent (Fig 8
). Therefore, although
III1-C has no specific effect on the synthesis of
FN, III1-C treatment does result in an overall
reduction in protein synthesis. The net effect is that
III1-Ctreated cells produce 60% to 65% less
FN per cell than do control-treated cultures. Although this may play a
part in the inhibited FN matrix assembly seen in
III1-Ctreated cells, it may not account for the
entire inhibition of matrix assembly, because FN synthesis is only
partially inhibited and because cells are able to produce FN fibrils
from the FN found in the medium and the FN coated on the
dish.17 In any case, the above data indicate that
III1-C inhibited FN matrix assembly and decreased
overall protein synthesis but did not have any specific effect on FN
synthesis. Thus, the inhibition of FN matrix assembly may be due in
part to the decrease in overall protein synthesis and in part to
competition during fibrillogenesis by direct interactions between
III1-C and FN.32 35 36
|
The matrix assembly results shown in Figs 6
and 7
suggest that
III1-C may inhibit VSMC proliferation by
inhibiting FN matrix assembly. If that is the case, other methods of
inhibiting FN matrix assembly might also be expected to inhibit the
proliferation of these cells. To test this hypothesis, HUASMCs were
treated with the anti-FN mAb L8, which has previously been shown to
inhibit FN matrix assembly.49 Treatment of
HUASMCs with mAb L8 resulted in a concentration-dependent inhibition of
DNA synthesis (Fig 9
), indicating that
inhibition of FN matrix assembly leads to inhibition of HUASMC
proliferation.
|
| Discussion |
|---|
|
|
|---|
5ß1 to focal contacts. However, III1-C did
inhibit FN matrix assembly by every cell type tested. Moreover,
inhibition of HUASMC FN matrix assembly by an anti-FN mAb also
inhibited DNA synthesis. These results suggest that
III1-C may inhibit VSMC DNA synthesis by
inhibiting FN matrix assembly.
Hedin et al in 198813 and
199715 demonstrated that a nonproliferative
contractile phenotype is maintained for longer periods when
cells are cultured on laminin in the presence of RGD peptides than when
cells are cultured on laminin alone. The RGD peptides in those studies
had at least two effects: (1) inhibition of FN matrix assembly and (2)
inhibition of RGD-binding integrins (eg,
5ß1 and
vß3).
Therefore, it was not possible to distinguish which effect of the RGD
peptides was most important for the regulation of VSMC growth. The
present study was designed to separate these two effects; by
culturing cells on a FN coating with III1-C in
the medium, we were able to inhibit FN matrix assembly without
inhibiting integrin binding to FN. The results indicate that inhibition
of FN matrix assembly is sufficient for the inhibition of VSMC
proliferation.
Treatment of HUASMCs with III1-C did not result
in an immediate inhibition of DNA synthesis; the effect was not seen
with treatment times of <5 hours but was seen with
24 hours of
treatment (Fig 2
). One possible explanation for this is that the cell
populations that are being treated with III1-C
are growing and are not synchronized in the cell cycle at the time of
addition of III1-C. Previous work has shown that
the ECM exerts its effects on the proliferation of fibroblasts at the
G1- to S-phase transition in the cell
cycle.40 41 If the same is true for
III1-C treatment of VSMCs, then the only cells
that will be affected immediately after the addition of
III1-C are the cells that are just entering S
phase; this is likely to be only a small proportion of the total cell
population. The work with fibroblasts has shown that after entering S
phase, cells no longer require attachment to the ECM to complete the
cell cycle. Although III1-C does not cause cells
to detach from the ECM, it is possible that it does exert its effects
in a cell cyclespecific manner as described above. If this is true,
then cells that entered S phase before the addition of
III1-C may not be affected; they may continue to
synthesize DNA at a normal rate. Only after their daughter cells have
traversed the cell cycle and come to the next G1-
to S-phase transition will III1-C inhibit DNA
synthesis in these cells. Thus, the effect of
III1-C on DNA synthesis may be seen to increase
over time because more and more cells have come to the critical part of
the cell cycle in which they are susceptible to control of DNA
synthesis by III1-C. Future experiments with
synchronized cell populations should help test this hypothesis for the
effect of III1-C on VSMC growth.
In the present study, III1-C inhibited the FN matrix assembly of every cell type tested (rat aortic SMCs, HUASMCs, A7r5 cells, IMR-90 cells, and HUVECs); however, III1-C inhibited the growth of only the normal diploid VSMCs. These findings can be interpreted in either of two ways: (1) of the cell types tested, only VSMCs depend on an intact FN matrix for proliferation, or (2) the inhibition of VSMC growth by III1-C is due to some other effect of III1-C on VSMCs (an effect that is thus far specific for primary VSMCs) and is not a result of the inhibition of FN matrix assembly by III1-C. The results obtained with the mAb L8 are consistent with the idea that inhibition of FN matrix assembly leads to inhibition of VSMC growth. Thus, it may be that normal diploid VSMCs are acutely sensitive to the presence of a FN matrix in their environment, whereas the other cell types tested do not require the FN matrix for growth. In any case, it is clear that III1-C exerts some effect that is specific to normal VSMCs; this unique ability may prove useful in clinical applications (see below).
The mechanism(s) of how inhibition of FN matrix assembly may lead to inhibition of VSMC DNA synthesis was not addressed in the present study, but several possible mechanisms can be envisioned. For example, it is possible that the fibrillar matrix form of FN can mediate specific signals that are not generated by dimeric FN. Experiments with CHO cell adhesion and migration support this idea.37 It is known that cell shape can exert a profound effect on the proliferation of various cells.50 51 52 Perhaps fibrillar FN induces a cellular morphology that is more conducive to growth than nonfibrillar FN. Although we were not able to detect significant differences in cell morphology after treatment with III1-C (particularly at treatment times of <48 hours), it is possible that more subtle changes do occur and that these lead to the inhibition of growth. Another possible mechanism is that the FN matrix (and its associated molecules) may serve as a reservoir for inhibitory growth factors (eg, transforming growth factor-ß) and that the lack of a FN matrix may result in greater exposure of the cells to these inhibitory growth factors. The opposite may also be true; the FN matrix may serve as a reservoir or cofactor for stimulatory growth factors. Subsequent studies will be aimed at distinguishing between these hypotheses.
Our results demonstrated that III1-C inhibited the growth of primary rat aortic SMCs but did not inhibit the growth of the rat aortic SMC line A7r5. Primary rat aortic SMCs and A7r5 cells share many similarities, including the expression of many VSMC-specific proteins. However, A7r5 and primary cells do show differences in the expression of some genes, eg, the transcription factor GATA-6.53 In addition, the A7r5 cell line is immortalized, indicating that the normal cell cycle controls that cause primary cells to senesce are disrupted in A7r5 cells. Our results indicate that A7r5 cells have lost their dependence on the presence of a FN matrix for growth. This loss of responsiveness to the ECM may be one fundamental difference between A7r5 cells and primary rat aortic SMCs and may relate to the immortalized growth of A7r5 cells.
The properties described here for III1-C make it a potentially attractive tool for use in the treatment of VSMC proliferative diseases, such as restenosis. Balloon angioplasty destroys the endothelial lining in the blood vessel and promotes the proliferation of VSMCs, which reduces the diameter of the vessel lumen.8 54 55 56 An ideal treatment for this process of restenosis would allow endothelial cells to proliferate and migrate back into the injured area, thereby reestablishing the antithrombogenic lumen wall, but would inhibit the proliferation of VSMCs so as to prevent a reduction of the lumen diameter. III1-C was found to inhibit the proliferation of VSMCs but not of several other cell types, including endothelial cells. Moreover, III1-C exerts its effects by being applied extracellularly; it does not need to be expressed by a cell in order to produce its effects. It is therefore attractive to speculate that III1-C (or a reagent with similar properties) may serve as a useful treatment for restenosis.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received March 20, 1997; accepted December 17, 1997.
| References |
|---|
|
|
|---|
2. Meredith JE Jr, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell. 1993;4:953961.[Abstract]
3.
Frisch SM, Francis H. Disruption of epithelial
cell-matrix interactions induces apoptosis. J Cell
Biol. 1994;124:619626.
4. Roskelley CD, Srebrow A, Bissell MJ. A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Curr Opin Cell Biol. 1995;7:736747.[Medline] [Order article via Infotrieve]
5.
Chamley-Campbell J, Campbell GR, Ross R. The smooth
muscle cell in culture. Physiol Rev. 1979;59:161.
6.
Thyberg J, Hedin U, Sjolund M, Palmberg L, Bottger BA.
Regulation of differentiated properties and proliferation of
arterial smooth muscle cells.
Arteriosclerosis. 1990;10:966990.
7. Campbell GR, Campbell JH. Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp Mol Pathol. 1985;42:139162.[Medline] [Order article via Infotrieve]
8.
Owens GK. Regulation of differentiation of vascular
smooth muscle cells. Physiol Rev. 1995;75:487517.
9. Schwartz SM, Mecham RP. The vascular smooth muscle cell: molecular and biological responses to the extracellular matrix. In: Mecham RP, ed. Biology of Extracellular Matrix. San Diego, Calif: Academic Press Inc; 1995:410.
10. Rhudy RW, McPherson JM. Influence of the extracellular matrix on the proliferative response of human skin fibroblasts to serum and purified platelet-derived growth factor. J Cell Physiol. 1988;137:185191.[Medline] [Order article via Infotrieve]
11.
Schor SL. Cell proliferation and migration on collagen
substrata in vitro. J Cell Sci. 1980;41:159175.
12. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors. Cell. 1996;87:10691078.[Medline] [Order article via Infotrieve]
13.
Hedin U, Bottger BA, Forsberg E, Johansson S, Thyberg
J. Diverse effects of fibronectin and laminin on phenotypic properties
of cultured arterial smooth muscle cells. J Cell
Biol. 1988;107:307319.
14. Hedin U, Thyberg J. Plasma fibronectin promotes modulation of arterial smooth-muscle cells from contractile to synthetic phenotype. Differentiation. 1987;33:239246.[Medline] [Order article via Infotrieve]
15. Hedin UL, Daum G, Clowes AW. Disruption of integrin alpha 5 beta 1 signaling does not impair PDGF-BB-mediated stimulation of the extracellular signal-regulated kinase pathway in smooth muscle cells. J Cell Physiol. 1997;172:109116.[Medline] [Order article via Infotrieve]
16. Mosher DF, Sottile J, Wu C, McDonald JA. Assembly of extracellular matrix. Curr Opin Cell Biol. 1992;4:810818.[Medline] [Order article via Infotrieve]
17. Hynes RO. Fibronectins. New York, NY: Springer-Verlag; 1990.
18. Pytela R, Pierschbacher MD, Ruoslahti E. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell. 1985;40:191198.[Medline] [Order article via Infotrieve]
19.
Pierschbacher MD, Ruoslahti E. Variants of the cell
recognition site of fibronectin that retain attachment-promoting
activity. Proc Natl Acad Sci U S A. 1984;81:59855988.
20.
McDonald JA, Quade BJ, Broekelmann TJ, LaChance R,
Forsman K, Hasegawa E, Akiyama S. Fibronectin's cell-adhesive domain
and an amino-terminal matrix assembly domain participate in its
assembly into fibroblast pericellular matrix. J Biol
Chem. 1987;262:29572967.
21.
Akiyama SK, Yamada SS, Chen WT, Yamada KM.
Analysis of fibronectin receptor function with monoclonal
antibodies: roles in cell adhesion, migration, matrix assembly, and
cytoskeletal organization. J Cell Biol. 1989;109:863875.
22.
Fogerty FJ, Akiyama SK, Yamada KM, Mosher DF.
Inhibition of binding of fibronectin to matrix assembly sites by
anti-integrin (alpha 5 beta 1) antibodies. J Cell Biol. 1990;111:699708.
23. Giancotti FG, Ruoslahti E. Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell. 1990;60:849859.[Medline] [Order article via Infotrieve]
24.
Nagai T, Yamakawa N, Aota S, Yamada SS, Akiyama SK,
Olden K, Yamada KM. Monoclonal antibody characterization of two distant
sites required for function of the central cell-binding domain of
fibronectin in cell adhesion, cell migration, and matrix assembly.
J Cell Biol. 1991;114:12951305.
25.
Wu C, Bauer JS, Juliano RL, McDonald JA. The alpha 5
beta 1 integrin fibronectin receptor, but not the alpha 5 cytoplasmic
domain, functions in an early and essential step in fibronectin matrix
assembly. J Biol Chem. 1993;268:2188321888.
26. Wu C, Keivens VM, O'Toole TE, McDonald JA, Ginsberg MH. Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix. Cell. 1995;83:715724.[Medline] [Order article via Infotrieve]
27.
Wennerberg K, Lohikangas L, Gullberg D, Pfaff M,
Johansson S, Fassler R. Beta 1 integrin-dependent and -independent
polymerization of fibronectin. J Cell Biol. 1996;132:227238.
28.
McKeown-Longo PJ, Mosher DF. Interaction of the
70,000-mol-wt amino-terminal fragment of fibronectin with the
matrix-assembly receptor of fibroblasts. J Cell Biol. 1985;100:364374.
29.
Quade BJ, McDonald JA. Fibronectin's amino-terminal
matrix assembly site is located within the 29-kDa amino-terminal domain
containing five type I repeats. J Biol Chem. 1988;263:1960219609.
30.
Schwarzbauer JE. Identification of the fibronectin
sequences required for assembly of a fibrillar matrix. J Cell
Biol. 1991;113:14631473.
31.
Sottile J, Schwarzbauer J, Selegue J, Mosher DF. Five
type I modules of fibronectin form a functional unit that binds to
fibroblasts and Staphylococcus aureus. J Biol
Chem. 1991;266:1284012843.
32.
Hocking DC, Sottile J, McKeown-Longo PJ. Fibronectin's
III-1 module contains a conformation-dependent binding site for the
amino-terminal region of fibronectin. J Biol Chem. 1994;269:1918319187.
33.
Aguirre KM, McCormick RJ, Schwarzbauer JE. Fibronectin
self-association is mediated by complementary sites within the
amino-terminal one-third of the molecule. J Biol Chem. 1994;269:2786327868.
34.
Chernousov MA, Fogerty FJ, Koteliansky VE, Mosher DF.
Role of the I-9 and III-1 modules of fibronectin in formation of an
extracellular fibronectin matrix. J Biol Chem. 1991;266:1085110858.
35.
Morla A, Ruoslahti E. A fibronectin self-assembly site
involved in fibronectin matrix assembly: reconstruction in a synthetic
peptide. J Cell Biol. 1992;118:421429.
36.
Hocking DC, Smith RK, McKeown-Longo PJ. A novel role
for the integrin-binding III-10 module in fibronectin matrix assembly.
J Cell Biol. 1996;133:431444.
37. Morla A, Zhang Z, Ruoslahti E. Superfibronectin is a functionally distinct form of fibronectin. Nature. 1994;367:193196.[Medline] [Order article via Infotrieve]
38. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:27452756.
39.
Freytag SO. Enforced expression of the c-myc oncogene
inhibits cell differentiation by precluding entry into a distinct
predifferentiation state in G0/G1. Mol Cell Biol. 1988;8:16141624.
40. Assoian RK, Marcantonio EE. The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J Clin Invest. 1996;98:24362439.[Medline] [Order article via Infotrieve]
41. Assoian RK, Zhu X. Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. Curr Opin Cell Biol. 1997;9:9398.[Medline] [Order article via Infotrieve]
42. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:1125.[Medline] [Order article via Infotrieve]
43.
Clark EA, Brugge JS. Integrins and signal transduction
pathways: the road taken. Science. 1995;268:233239.
44. Giancotti FG, Mainiero F. Integrin-mediated adhesion and signaling in tumorigenesis. Biochim Biophys Acta. 1994;1198:4764.[Medline] [Order article via Infotrieve]
45.
LaFlamme SE, Akiyama SK, Yamada KM. Regulation of
fibronectin receptor distribution. J Cell Biol. 1992;117:437447.
46.
Maher PA, Pasquale EB, Wang JY, Singer SJ.
Phosphotyrosine-containing proteins are concentrated in focal adhesions
and intercellular junctions in normal cells. Proc Natl Acad Sci
U S A. 1985;82:65766580.
47. Burridge K, Fath K, Kelly T, Nuckolls G, Turner C. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol. 1988;4:487525.
48.
Romer LH, Burridge K, Turner CE. Signaling between the
extracellular matrix and the cytoskeleton: tyrosine
phosphorylation and focal adhesion assembly. Cold
Spring Harbor Symp Quant Biol. 1992;57:193202.
49. Chernousov MA, Faerman AI, Frid MG, Printseva OY, Koteliansky VE. Monoclonal antibody to fibronectin which inhibits extracellular matrix assembly. FEBS Lett. 1987;217:124128.[Medline] [Order article via Infotrieve]
50.
Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE.
Geometric control of cell life and death. Science. 1997;276:14251428.
51. Ingber DE. Tensegrity: the architectural basis of cellular mechanotransduction. Annu Rev Physiol. 1997;59:575599.[Medline] [Order article via Infotrieve]
52.
Mrksich M, Chen CS, Xia Y, Dike LE, Ingber DE,
Whitesides GM. Controlling cell attachment on contoured surfaces with
self-assembled monolayers of alkanethiolates on gold. Proc Natl
Acad Sci U S A. 1996;93:1077510778.
53. Morrisey EE, Ip HS, Lu MM, Parmacek MS. GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm. Dev Biol. 1996;177:309322.[Medline] [Order article via Infotrieve]
54.
Liu MW, Roubin GS, King SB III. Restenosis
after coronary angioplasty: potential biologic determinants and
role of intimal hyperplasia. Circulation. 1989;79:13741387.
55. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:12841293.[Abstract]
56. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801809.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
H.-Y. Chiang, V. A. Korshunov, A. Serour, F. Shi, and J. Sottile Fibronectin Is an Important Regulator of Flow-Induced Vascular Remodeling Arterioscler. Thromb. Vasc. Biol., July 1, 2009; 29(7): 1074 - 1079. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Wang, C.-H. Chen, S.-M. Hwang, W.-W. Lin, C.-H. Huang, W.-Y. Lee, Y. Chang, and H.-W. Sung Spherically Symmetric Mesenchymal Stromal Cell Bodies Inherent with Endogenous Extracellular Matrices for Cellular Cardiomyoplasty Stem Cells, March 1, 2009; 27(3): 724 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Khavandi, A. S. Greenstein, K. Sonoyama, S. Withers, A. Price, R. A. Malik, and A. M. Heagerty Myogenic tone and small artery remodelling: insight into diabetic nephropathy Nephrol. Dial. Transplant., February 1, 2009; 24(2): 361 - 369. [Full Text] [PDF] |
||||
![]() |
C.-H. Chen, H.-J. Wei, W.-W. Lin, I. Chiu, S.-M. Hwang, C.-C. Wang, W.-Y. Lee, Y. Chang, and H.-W. Sung Porous tissue grafts sandwiched with multilayered mesenchymal stromal cell sheets induce tissue regeneration for cardiac repair Cardiovasc Res, October 1, 2008; 80(1): 88 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhou, R. G. Rowe, N. Hiraoka, J. P. George, D. Wirtz, D. F. Mosher, I. Virtanen, M. A. Chernousov, and S. J. Weiss Fibronectin fibrillogenesis regulates three-dimensional neovessel formation Genes & Dev., May 1, 2008; 22(9): 1231 - 1243. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sonoyama, A. Greenstein, A. Price, K. Khavandi, and T. Heagerty Review: Vascular remodeling: implications for small artery function and target organ damage Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 129 - 137. [Abstract] [PDF] |
||||
![]() |
J. Sottile, F. Shi, I. Rublyevska, H.-Y. Chiang, J. Lust, and J. Chandler Fibronectin-dependent collagen I deposition modulates the cell response to fibronectin Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1934 - C1946. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Meng, Z. Wang, Y. Hoi, L. Gao, E. Metaxa, D. D. Swartz, and J. Kolega Complex Hemodynamics at the Apex of an Arterial Bifurcation Induces Vascular Remodeling Resembling Cerebral Aneurysm Initiation Stroke, June 1, 2007; 38(6): 1924 - 1931. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gui, K. Wojciechowski, C. D. Gildner, H. Nedelkovska, and D. C. Hocking Identification of the Heparin-binding Determinants within Fibronectin Repeat III1: ROLE IN CELL SPREADING AND GROWTH J. Biol. Chem., November 17, 2006; 281(46): 34816 - 34825. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Brassard, F. Amiri, G. Thibault, and E. L. Schiffrin Role of Angiotensin Type-1 and Angiotensin Type-2 Receptors in the Expression of Vascular Integrins in Angiotensin II-Infused Rats Hypertension, January 1, 2006; 47(1): 122 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Otis, S. Campbell, M. D. Payet, and N. Gallo-Payet Angiotensin II Stimulates Protein Synthesis and Inhibits Proliferation in Primary Cultures of Rat Adrenal Glomerulosa Cells Endocrinology, February 1, 2005; 146(2): 633 - 642. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ambesi, R. M. Klein, K. M. Pumiglia, and P. J. McKeown-Longo Anastellin, a Fragment of the First Type III Repeat of Fibronectin, Inhibits Extracellular Signal-Regulated Kinase and Causes G1 Arrest in Human Microvessel Endothelial Cells Cancer Res., January 1, 2005; 65(1): 148 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Klein, M. Zheng, A. Ambesi, L. Van De Water, and P. J. McKeown-Longo Stimulation of extracellular matrix remodeling by the first type III repeat in fibronectin J. Cell Sci., November 15, 2003; 116(22): 4663 - 4674. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wilson, A. V. Ljubimov, A. O. Morla, S. Caballero, L. C. Shaw, P. E. Spoerri, R. W. Tarnuzzer, and M. B. Grant Fibronectin Fragments Promote Human Retinal Endothelial Cell Adhesion and Proliferation and ERK Activation through {alpha}5{beta}1 Integrin and PI 3-Kinase Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1704 - 1715. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sottile and D. C. Hocking Fibronectin Polymerization Regulates the Composition and Stability of Extracellular Matrix Fibrils and Cell-Matrix Adhesions Mol. Biol. Cell, October 1, 2002; 13(10): 3546 - 3559. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Simper, P. G. Stalboerger, C. J. Panetta, S. Wang, and N. M. Caplice Smooth Muscle Progenitor Cells in Human Blood Circulation, September 3, 2002; 106(10): 1199 - 1204. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Rossi, M. Cavallin, A. S Belloni, G. Mazzocchi, G. G Nussdorfer, A. C Pessina, and S. Sartore Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension Cardiovasc Res, July 1, 2002; 55(1): 178 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Wierzbicka-Patynowski and J. E. Schwarzbauer Regulatory Role for Src and Phosphatidylinositol 3-Kinase in Initiation of Fibronectin Matrix Assembly J. Biol. Chem., May 24, 2002; 277(22): 19703 - 19708. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Moiseeva Adhesion receptors of vascular smooth muscle cells and their functions Cardiovasc Res, December 1, 2001; 52(3): 372 - 386. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Fischer, M. G. Kinsella, B. Levkau, A. W. Clowes, and T. N. Wight Retroviral Overexpression of Decorin Differentially Affects the Response of Arterial Smooth Muscle Cells to Growth Factors Arterioscler. Thromb. Vasc. Biol., May 1, 2001; 21(5): 777 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wen, J. Gu, Y. Liu, P. H. Wang, Y. Sun, and J. L. Nadler Overexpression of 12-Lipoxygenase Causes Cardiac Fibroblast Cell Growth Circ. Res., January 19, 2001; 88(1): 70 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. Intengan and E. L. Schiffrin Structure and Mechanical Properties of Resistance Arteries in Hypertension : Role of Adhesion Molecules and Extracellular Matrix Determinants Hypertension, September 1, 2000; 36(3): 312 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Kinsella, J. W. Fischer, D. P. Mason, and T. N. Wight Retrovirally Mediated Expression of Decorin by Macrovascular Endothelial Cells. EFFECTS ON CELLULAR MIGRATION AND FIBRONECTIN FIBRILLOGENESIS IN VITRO J. Biol. Chem., April 28, 2000; 275(18): 13924 - 13932. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Hocking, J. Sottile, and K. J. Langenbach Stimulation of Integrin-mediated Cell Contractility by Fibronectin Polymerization J. Biol. Chem., March 31, 2000; 275(14): 10673 - 10682. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Suniara, E. J. Jenkinson, and J. J.T. Owen An Essential Role for Thymic Mesenchyme in Early T Cell Development J. Exp. Med., March 20, 2000; 191(6): 1051 - 1056. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Pickering, L. H. Chow, S. Li, K. A. Rogers, E. F. Rocnik, R. Zhong, and B. M. C. Chan {alpha}5{beta}1 Integrin Expression and Luminal Edge Fibronectin Matrix Assembly by Smooth Muscle Cells after Arterial Injury Am. J. Pathol., February 1, 2000; 156(2): 453 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Sottile, D. Hocking, and K. Langenbach Fibronectin polymerization stimulates cell growth by RGD-dependent and -independent mechanisms J. Cell Sci., January 12, 2000; 113(23): 4287 - 4299. [Abstract] [PDF] |
||||
![]() |
K. J. Langenbach and J. Sottile Identification of Protein-disulfide Isomerase Activity in Fibronectin J. Biol. Chem., March 12, 1999; 274(11): 7032 - 7038. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ross Atherosclerosis -- An Inflammatory Disease N. Engl. J. Med., January 14, 1999; 340(2): 115 - 126. [Full Text] [PDF] |
||||
![]() |
R. Christopher, S. Judge, P. Vincent, P. Higgins, and P. McKeown-Longo The amino-terminal matrix assembly domain of fibronectin stabilizes cell shape and prevents cell cycle progression J. Cell Sci., January 10, 1999; 112(19): 3225 - 3235. [Abstract] [PDF] |
||||
![]() |
S. Bourdoulous, G. Orend, D. A. MacKenna, R. Pasqualini, and E. Ruoslahti Fibronectin Matrix Regulates Activation of RHO and CDC42 GTPases and Cell Cycle Progression J. Cell Biol., October 5, 1998; 143(1): 267 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Sechler and J. E. Schwarzbauer Control of Cell Cycle Progression by Fibronectin Matrix Architecture J. Biol. Chem., October 2, 1998; 273(40): 25533 - 25536. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Sottile, D. Hocking, and P. Swiatek Fibronectin matrix assembly enhances adhesion-dependent cell growth J. Cell Sci., January 10, 1998; 111(19): 2933 - 2943. [Abstract] [PDF] |
||||
![]() |
K. Tamura, Y. E. Chen, M. Lopez-Ilasaca, L. Daviet, N. Tamura, T. Ishigami, M. Akishita, I. Takasaki, Y. Tokita, R. E. Pratt, et al. Molecular Mechanism of Fibronectin Gene Activation by Cyclic Stretch in Vascular Smooth Muscle Cells J. Biol. Chem., October 27, 2000; 275(44): 34619 - 34627. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Tomasini-Johansson, N. R. Kaufman, M. G. Ensenberger, V. Ozeri, E. Hanski, and D. F. Mosher A 49-Residue Peptide from Adhesin F1 of Streptococcus pyogenes Inhibits Fibronectin Matrix Assembly J. Biol. Chem., June 22, 2001; 276(26): 23430 - 23439. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |